,question,gt_rec1,gt_rec2,gt_rec3,gt_avoid,gt_reason,prompt,raw_answer,answer1,pro1,cons1,answer2,pro2,cons2,source1,source2,source3,source4,source5,source6
0,"40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations
",Infliximab,Tofacitinib,,vedolizumab,IFX is ideal choice as biologically naïve with EIM.,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Infliximab (IFX)"",
  ""advantages"": ""Best choice for patients with extraintestinal manifestations, such as articular involvement, and effective for newly diagnosed moderate UC."",
  ""disadvantages"": ""Potential side effects, including increased risk of infections and infusion reactions.""
},
{
  ""drug_name"": ""Golimumab (GOL)"",
  ""advantages"": ""Second-best choice for patients with extraintestinal manifestations and effective for moderate UC."",
  ""disadvantages"": ""Less effective than Infliximab for extraintestinal manifestations and potential side effects, including increased risk of infections.""
}",Infliximab (IFX),"Best choice for patients with extraintestinal manifestations, such as articular involvement, and effective for newly diagnosed moderate UC.","Potential side effects, including increased risk of infections and infusion reactions.",Golimumab (GOL),Second-best choice for patients with extraintestinal manifestations and effective for moderate UC.,"Less effective than Infliximab for extraintestinal manifestations and potential side effects, including increased risk of infections.","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)
Best: Ustekinumab (USTE)
2nd Best: Vedoluzimab (VEDO)
3rd Best:
4th Best:
5th Best: ",,
1,"70 year old female with newly diagnosed severe UC
",Ustekinumab,Vedolizumab,,Infliximab,"Given advanced age, IFX not preferred as first choice","Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Ustekinumab (USTE)"",
  ""advantages"": ""Best choice for patients aged over 65 with comorbidities due to its safety aspects data."",
  ""disadvantages"": ""Not the best choice for extraintestinal manifestations.""
},
{
  ""drug_name"": ""Vedolizumab (VEDO)"",
  ""advantages"": ""Another top choice for patients aged over 65 with comorbidities due to its safety aspects data."",
  ""disadvantages"": ""Not the best choice for extraintestinal manifestations and may not be the best option during pregnancy.""
}",Ustekinumab (USTE),Best choice for patients aged over 65 with comorbidities due to its safety aspects data.,Not the best choice for extraintestinal manifestations.,Vedolizumab (VEDO),Another top choice for patients aged over 65 with comorbidities due to its safety aspects data.,Not the best choice for extraintestinal manifestations and may not be the best option during pregnancy.,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)
Best: Ustekinumab (USTE)
2nd Best: Vedoluzimab (VEDO)
3rd Best:
4th Best:
5th Best: ",,
2,"35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance
",Tofacitinib,Ustekinumab,,,Testing 2nd line treatment to patients previously exposed to anti-TNFa,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Ustekinumab (USTE)"",
  ""advantages"": ""Effective in patients with prior failure to anti-TNF agents like Infliximab, lower risk of immunogenicity, and suitable for patients with extraintestinal manifestations."",
  ""disadvantages"": ""Less data available compared to other biologics, may have a slower onset of action, and requires subcutaneous injections.""
}",Ustekinumab (USTE),"Effective in patients with prior failure to anti-TNF agents like Infliximab, lower risk of immunogenicity, and suitable for patients with extraintestinal manifestations.","Less data available compared to other biologics, may have a slower onset of action, and requires subcutaneous injections.",,,,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Vedolizumab
Best: Infliximab (IFX)
2nd Best: Ustekinumab (USTE), Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)",,
3,"60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure
",Ustekinumab,Vedolizumab,,Tofacitinib,Testing contraindications to first line IFX. TFC not recommended because of increased LDL-C and MACE risk,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Ustekinumab (USTE)"",
  ""advantages"": ""Best choice for patients with age > 65 and comorbidities, as it has a favorable safety profile."",
  ""disadvantages"": ""Not the best choice for pregnant patients, as it is ranked 3rd best in this category.""
},
{
  ""drug_name"": ""Vedolizumab (VEDO)"",
  ""advantages"": ""2nd best choice for patients with age > 65 and comorbidities, and best choice for patients currently under maintenance."",
  ""disadvantages"": ""Not the best choice for pregnant patients, as it is ranked 3rd best in this category.""
}",Ustekinumab (USTE),"Best choice for patients with age > 65 and comorbidities, as it has a favorable safety profile.","Not the best choice for pregnant patients, as it is ranked 3rd best in this category.",Vedolizumab (VEDO),"2nd best choice for patients with age > 65 and comorbidities, and best choice for patients currently under maintenance.","Not the best choice for pregnant patients, as it is ranked 3rd best in this category.","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)
Best: Ustekinumab (USTE)
2nd Best: Vedoluzimab (VEDO)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Currently under maintenance
Best: Vedoluzimab (VEDO)
2nd Best: Infliximab (IFX)
3rd Best: Ustekinumab (USTE), Golimumab (GOL)
4th Best: Adalimumab (ADA)
5th Best: ",,
4,"38 year old female with newly diagnosed moderate UC and psoriasis
",Ustekinumab,,,,Test treatment of specific EIM and IBD,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know,,,,,,,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)
Best: Ustekinumab (USTE)
2nd Best: Vedoluzimab (VEDO)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)",,
5,"25 year old pregnant woman with severe distal ulcerative colitis
",Infliximab,Vedolizumab,Ustekinumab,,Infliximab has best safety data in pregnancy (due to experience),"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","[
  {
    ""drug_name"": ""Infliximab (IFX)"",
    ""advantages"": ""Best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC"",
    ""disadvantages"": ""Potential side effects, risk of infusion reactions, and immunogenicity""
  },
  {
    ""drug_name"": ""Golimumab (GOL)"",
    ""advantages"": ""Second best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC"",
    ""disadvantages"": ""Less data available on safety and efficacy during pregnancy compared to Infliximab, potential side effects, and immunogenicity""
  }
]",Infliximab (IFX),"Best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC","Potential side effects, risk of infusion reactions, and immunogenicity",Golimumab (GOL),"Second best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC","Less data available on safety and efficacy during pregnancy compared to Infliximab, potential side effects, and immunogenicity","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ",,
6,"56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis
",Infliximab,Adalimumab,,,Dual indications,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Infliximab (IFX)"",
  ""advantages"": ""Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis"",
  ""disadvantages"": ""Risk of infusion reactions and potential for immunogenicity""
},
{
  ""drug_name"": ""Adalimumab (ADA)"",
  ""advantages"": ""Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis; subcutaneous administration"",
  ""disadvantages"": ""Potential for immunogenicity and injection site reactions""
}",Infliximab (IFX),Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis,Risk of infusion reactions and potential for immunogenicity,Adalimumab (ADA),Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis; subcutaneous administration,Potential for immunogenicity and injection site reactions,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)
Best: Ustekinumab (USTE)
2nd Best: Vedoluzimab (VEDO)
3rd Best:
4th Best:
5th Best: ",,
7,"38 year old man with severe ulcerative colitis and has lost response to vedolizumab
",Tofacitinib or ,Ustekinumab,,,Biologic failure,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{
  ""drug_name"": ""Infliximab (IFX)"",
  ""advantages"": ""Best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis"",
  ""disadvantages"": ""Risk of infusion reactions, potential for immunogenicity, and increased risk of infections""
},
{
  ""drug_name"": ""Ustekinumab (USTE)"",
  ""advantages"": ""Second best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis"",
  ""disadvantages"": ""Less data available compared to Infliximab, potential for immunogenicity, and increased risk of infections""
}",Infliximab (IFX),"Best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis","Risk of infusion reactions, potential for immunogenicity, and increased risk of infections",Ustekinumab (USTE),"Second best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis","Less data available compared to Infliximab, potential for immunogenicity, and increased risk of infections","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Currently under maintenance
Best: Vedoluzimab (VEDO)
2nd Best: Infliximab (IFX)
3rd Best: Ustekinumab (USTE), Golimumab (GOL)
4th Best: Adalimumab (ADA)
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Vedolizumab
Best: Infliximab (IFX)
2nd Best: Ustekinumab (USTE), Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best:
5th Best: ",,
8,"28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago
",Vedolizumab,Ustekinumab,,,Anti-TNFs and JAK inhs have associations/concerns with malignancies,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know,,,,,,,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ",,
9,36 year old woman with moderate ulcerative colitis and multiple sclerosis,Ozanimod,Etrasimod,,,Dual indications,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on one of the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know,,,,,,,"title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)
Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)
3rd Best:
4th Best:
5th Best: ","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL)
3rd Best: Adalimumab (ADA)
4th Best: Ustekinumab (USTE)
5th Best: Vedoluzimab (VEDO)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis
Best: Vedoluzimab (VEDO)
2nd Best: Adalimumab (ADA)
3rd Best: Infliximab (IFX)
4th Best: Ustekinumab (USTE)
5th Best: Golimumab (GOL)","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 3

modal: table

text: Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy
Best: Infliximab (IFX)
2nd Best: Golimumab (GOL), Adalimumab (ADA)
3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)
4th Best:
5th Best: ",,
